Someone close to you is likely to be affected by endometriosis, as it's estimated that one in ten women of childbearing age worldwide has this condition. For many women, endometriosis is an exceptionally painful ailment, causing both chronic and acute types of pain that disrupt their daily lives. Consequently, women with endometriosis encounter challenges in their workplaces, studies, relationships with friends and family, and various social situations.
Despite its profound impact on patients, their loved ones, and society at large, endometriosis remains relatively unfamiliar. From the onset of symptoms, patients often endure up to a decade-long wait for a diagnosis.
Raising awareness is crucial for early diagnosis and treatment, particularly because it commonly affects girls and young women during their most formative years. The disruptions to their schooling and work can have long-term repercussions, and their interactions with family and friends are also strained.
March is recognized as Endometriosis Awareness Month. Gesynta Pharma is committed to the development of improved treatments for individuals enduring the challenges of endometriosis.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.